within Pharmacolibrary.Drugs.ATC.N;

model N07XX21
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.8,
    Cl             = 0.24 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 45 / 1000000,
    adminCount     = 1,
    Vd             = 0.013,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Eplontersen is an antisense oligonucleotide inhibitor of transthyretin (TTR) synthesis, aiming to reduce serum TTR protein levels. It is developed for the treatment of hereditary transthyretin-mediated (hATTR) amyloidosis with polyneuropathy in adults. In 2023, Eplontersen (brand name Wainua) was granted FDA approval for this indication.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters estimated for subcutaneous administration in adult patients; no peer-reviewed publication with detailed PK model found as of June 2024.</p><h4>References</h4><ol></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end N07XX21;
